Imani Fooladi Abbas Ali, Mahmoodzadeh Hosseini Hamideh, Amani Jafar
Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
Iran J Cancer Prev. 2015 May;8(3):e2326. doi: 10.17795/ijcp2326. Epub 2015 May 22.
Today, Lack of efficient therapeutic strategy for breast cancer (the most common cause of death in women) is one of the momentous problematic topics for all health care committees. Designing new specific vaccine, based on antigens located on the surface of cancer cells can be useful. Over expression of ROR1, lacked of HER2/neu, and hormone receptors on cell surface in the breast cancer, introduce this protein as an appropriate candidate for designing cancer vaccine.
We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.
Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct. In addition, the stability, physic-chemical properties and allergic potency of designed fusion protein were investigated by valid bioinformatics software.
Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.
The ROR-1 with an enterotoxin B could be a potent vaccine for breast cancer.
如今，缺乏针对乳腺癌（女性最常见的死因）的有效治疗策略是所有医疗保健委员会面临的重大问题之一。基于癌细胞表面抗原设计新型特异性疫苗可能会有所帮助。乳腺癌细胞表面ROR1的过度表达、HER2/neu的缺乏以及激素受体的缺失，使得这种蛋白质成为设计癌症疫苗的合适候选者。
我们假设受体酪氨酸激酶样孤儿受体1（ROR-1）的细胞外结构域与超抗原如葡萄球菌肠毒素B一起可能是一种有效的耐药性乳腺癌疫苗。
在此，我们评估了生物信息学分析结果，以确定这种嵌合构建体的抗肿瘤免疫特性。此外，通过有效的生物信息学软件研究了设计的融合蛋白的稳定性、理化性质和过敏潜力。
我们的结果表明，嵌合模型能够刺激T细胞和B细胞介导的免疫反应，具有可接受的可及性和溶解性，但无任何致敏性。
ROR-1与肠毒素B可能是一种有效的乳腺癌疫苗。
